Achieve Life shares surge 14.48% after-hours as FDA accepts NDA for cytisinicline and Citizens initiates coverage with $19 price target.

Achieve Life Sciences (ACHV) surged 14.48% in after-hours trading following two key developments: the FDA’s acceptance of its New Drug Application (NDA) for cytisinicline, a smoking cessation treatment, and coverage initiation by Citizens with a “Market Outperform” rating and a $19 price target. The NDA acceptance, with a PDUFA date of June 20, 2026, marks a critical regulatory milestone, while the analyst report highlighted cytisinicline’s competitive differentiation and a 90% estimated approval probability. These events bolstered investor confidence in the company’s prospects, overshadowing a recent earnings miss and reinforcing optimism about its commercialization strategy and market potential.